Why the study?
Does apixaban improve efficacy and safety compared to standard therapies in patients requiring anticoagulation for VTE prevention, AF, or ACS?
Does apixaban improve efficacy and safety compared to standard therapies in patients requiring anticoagulation for VTE prevention, AF, or ACS?
Apixaban is an effective and safe oral anticoagulant for VTE prevention after orthopedic surgery and stroke prevention in atrial fibrillation, but increases bleeding risk when added to antiplatelet therapy in acute coronary syndrome.
No takes yet. Share an insight, caveat, or question.
Supports apixaban in VTE and AF settings; leaves open net benefit when added in ACS.
Edith A. Nutescu (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: